2022 Update on the Treatment of Pituitary Tumors - On Demand

Wednesday, June 1, 2022, 8:45 AM - Saturday, July 1, 2023, 11:00 PM

This didactic and case-based educational course updates attendees on the latest developments in ongoing basic and translational science as well as the clinical management of patients with pituitary conditions.This course aims to improve patient care and outcomes through evidence-based discussion of clinical practice guidelines and emerging therapies. The goal is to assess and update current practices to promote earlier diagnosis and treatment of pituitary diseases. The multidisciplinary nature of the course will allow for the dissemination of knowledge across the variety of practitioners caring for patients with pituitary diseases.

Who Should Attend

This course is intended for endocrinologists, neurosurgeons, otolaryngologists, radiation oncologists, neurologists, ophthalmologists, neuro-oncologists, family medicine and internal medicine physicians, physicians in training and other allied health professionals who treat and manage patients with pituitary diseases.

On Demand Content

Included with your purchase of this on demand are recording and PDFs of 8 Lectures plus two Q&A sessions and a Tumor Board based on cases attendees submitted prior to the live course in April 2022. Select the 'Register' tab at the top of this page to purchase this program. Once you have successfully registered, access to the course materials will be available under the 'Course Content' tab.

This on demand program will be available for purchase until April 1, 2023.
Access to the videos and claiming credit will be available until July 1, 2023.

1. Summarize ongoing clinical trials and emerging therapies for the treatment of Cushing’s and acromegaly
2. Discuss surgical outcomes, complications and risk management for pituitary and skull base tumors
3. Evaluate endoscopic surgery with the use of patient reported outcomes
4. Discuss integrative therapies and use of patient reported outcomes for pituitary patients
5. Present recent data on mechanisms and biomarkers for the development of aggressive and malignant pituitary tumors
6. Debate treatment decisions supporting the use and timing of new therapies for aggressive and malignant pituitary tumors
7. Review mechanisms, diagnosis and treatment of immunotherapy-induced hypophysitis

On Demand Access Fees

• Physicians (MDs, PhDs and DOs): $150
• Residents, Fellows, Advanced Practice Providers, Nurses, and Other Healthcare Providers: $100
• Industry Professionals: $265 

Discounts/Promotions

• A registration discount is available for MSK Alumni, MSK Cancer Alliance, and Cancer Care Partners to attend a MSK CME course. If you are a member of one of these groups, contact [email protected] for details.
• Registration is complimentary for all MSK employees; however, you must complete registration through the 'Register' tab above in order to attend this course. If you are registered for this course and are unable to attend, please notify [email protected].

Please note that after your payment has been processed, no further promotional discounts or adjustments will be made to your registration.

Registration fees for the online CME activity are non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

 Recorded/Review Date: April 9, 2022; Original Release Date: June 1, 2022; Termination Date: July 1, 2023

MSK Course Directors 

Viviane Tabar, MD
Director, Pituitary & Skull Base Tumor Center
Theresa Feng Chair in Neurosurgical Oncology
Chair, Department of Neurosurgery

Eliza B. Geer, MD
Medical Director, Pituitary & Skull Base Tumor Center
Associate Attending
Endocrinology Service
Department of Medicine

Marc A. Cohen, MD, MPH
Surgical Director, Pituitary * Skull Base Tumor Center
Associate Attending
Head and Neck Service
Department of Surgery

 

Invited Course Faculty

Nienke Biermasz, MD
Professor Internal Medicine
Leiden University
Leiden, The Netherlands

Isabella Lupi, MD, PhD
Endocrinology Unit
Pisa University Hospital
Pisa, Italy

Gérald Raverot, MD, PhD
Hospices Civils of Lyon - Lyon I University
Lyon, France

 

MSK Course Faculty

Kathryn Beal, MD
Associate Attending
External Beam Radiotherapy Service
Brachytherapy Service
Department of Radiation Oncology

Monica Girotra, MD
Associate Attending
Endocrinology Service
Department of Medicine

Sasan Karimi, MD
Director, MSKCC 55th Street Radiology
Associate Attending
Neuroradiology Service
Department of Radiology

Andrew Lin, MD
Assistant Attending
Brain Tumor Service
Department of Neurology

Jun Mao, MD, MSCE
Chief, Integrative Medicine Service

Shelly Latte-Naor, MD
Director, Mind-Body Medicine
Integrative Medicine Service

Marc Rosenblum, MD
Chief, Neuropathology

 

  

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.